Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022

  • Scientists from Austria, Belgium, France, and the Netherlands awarded for groundbreaking work on practical PRRS control methods     
  • Boehringer Ingelheim sponsors PRRS Award for the ninth time and supports research with 75,000 EUR in total 

Porcine Reproductive and Respiratory Syndrome (PRRS), a virus that affects both growing piglets and adult pigs and leads to reproductive failure in breeding stock and respiratory tract illness, imposes a significant financial burden on swine producers all over the world: The total cost to the industry has been estimated at 1.5 billion EUR annually in the European Union alone.1
Developing new, practical PRRS control methods that are based on scientific evidence in addition to vaccination are highly relevant.   

In 2014, Boehringer Ingelheim initiated the European PRRS Research Award to encourage studies into new means of combating PRRS and to further develop new practical methods for PRRS control: These practical methods can range from diagnostics to biosecurity and management. Every year, three outstanding research proposals are awarded with 75,000 EUR in total.  

“The European PRRS Research Award brings science and veterinary practice together and promotes work that makes a difference for swine practitioners and their animals. We are pleased that the PRRS Award is so well received, and we are glad to support the promotion of excellent scientific work that has high value for practice,” shared Markus Hammer, Global Head of Swine at Boehringer Ingelheim.  

This year, the independent award jury honored the work of scientists from four European countries: 

  • Diedrich Hendrickx, the Netherlands, and Merel Postma, Belgium, for the development of an ADKAR change management model to wean piglets free of PRRS wild type virus and understand the farmers objection towards a PRRS free future. The final goal of this project is to coach the farm how to set up and follow an individual PRRS control plan. 
  •  Emil Lagumdzic, Austria, for the gene expression profiling of peripheral blood mononuclear cells and CD8+ T cells from gilts after PRRSV infection. Better understanding the role of immune responses can enable a targeted development of efficacious vaccines. 
  • Arnaud Lebret, France, for a descriptive study on PRRSV detection by qPCR in blood samples collected in positive stable herds following mass vaccination of sows with a MLV vaccine. Objectifying the frequency of detection of vaccine strains would help practitioners in their choice when implementing vaccinal strategies against PRRSV.

For more information on the European PRRS Award, please visit 


1 internal data on file 

Boehringer Ingelheim Animal Health 

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. For more information visit

Boehringer Ingelheim 

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. 

Source: Boehringer Ingelheim News Release